ILC 2013 ---48th annual meeting of the European Association for the Study of the Liver
Poster 780
Journal of Hepatology. 2013, 58 (suppl No.1):s317-s318.
B.-F. Wu1,2*, J.-Y. Yang2,
Y. Liu1, X.-Q. Wang1, X.-H. Huang1, Z.-S. Xiao1,
X.-S. Li1, M. Yang1, Y. Zhou2, J. Yang2,
F.-Q. Li1, H. Huang1, Q.-M. Qiu1
1Gastroenterology and Hepatology
Center, Southern Medical
University Renkang
Hospital, Dongguan, 2Guangzhou
Pubang Bio-Immunological Tech Research Institute, Guangzhou, China.
*bangfu.wu@163.com
Background and aims: To observe the
clinical efficacy of anti-HBV-DC and anti-HBV-MTL (anti-HBV-DC-MTL), the
dendritic cells(DC) and mixed T lymphocyte(MTL) originating from peripheral
blood mononuclear cells(PBMC) sensitized by HBsAg, in combination with
telbivudine, in HBeAg positive chronic hepatitis B virus(HBV) infection.
Methods: 46 HBeAg positive chronic HBV infection including 34 males and
12 females aged 17-50 years were recruited in the study including 15 chronic
HBV carriers, 16 chronic hepatitis B(CHB) patients with ALT≤2ULN and 15 CHB
patients with ALT>2ULN.
PBMCs were obtained from 50ml of heparinized peripheral blood through density
gradient centrifuge. Anti-HBV-DC was proliferated from adherence PBMCs under
the induction by GM-CSF and IL-4, and sensitized with hepatitis B vaccine
containing 50µg HBsAg. Anti-HBV-MTL was proliferated from no-adherence PBMCs
under the induction by IL-2, IL-12 and anti-HBV-DC. Anti-HBV-DC was harvested
on day 7 and injected, half hypodermically and half intravenously, to the
patient once every two weeks for 12 times totally. Anti-HBV-MTL was harvested
on day 14 and injected intravenously to the patient once every two weeks for 12
times totally. Telbivudine was taken 600mg daily. Quantitative HBVM(TRFIA) and
HBVDNA and hepatic functions were evaluated at week 0, 4, 12, and 24.
Results: Mean of HBsAg, HBeAg and HBVDNA decreased significantly,
while mean of HBeAb increased obviously at week 4, 12 and 24, HBeAg negative
conversion rate were 38.13%(18/46), 43.47(20/46) and 50.00%(23/46)
respectively, HBeAb positive conversion rate were 28.26%(13/46), 39.13%(18/46)
and 45.65%(21/46), HBeAg seroconversion rate were 26.09%(12/46), 36.96%(17/46) and
45.65%(21/46), HBVDNA negative conversion rate were 36.96%(17/46),
43.48%(20/46) and 69.57%(32/46), ALT normalization rate were 22.58%(7/31),
61.29%(19/31) and 80.65%(25/31), and HBeAg seroconversion rate was 13.33%(2/15),
20.00%(3/15) and 26.67%(4/15) in chronic HBV carriers, 25.00%(4/16),
37.50%(6/16) and 43.75%(7/16) in patients with ALT≤2ULN, and 40.00%(6/15),
53.33%(8/15) and 66.67%(10/15) in patients with ALT>2ULN.
The rate of adverse effect was 2.98% observed in re-infusion of anti-HBV-DC and
anti-HBV-MTL.
Conclusions: Anti-HBV-DC and anti-HBV-MTL (anti-HBV-DC-MTL) in
combination with telbivudine can be considered as a safe and efficient approach
for HBeAg positive chronic HBV infection, which may effectively inhibit the
viral replication, lower rapidly HBsAg, HBeAg and HBVDNA, improve the
production of HBeAb, and increase the HBeAg seroconversion rate.
Author Keywords: Dendritic cells (DC); Mixed
T lymphocyte (MTL); Hepatitis B virus (HBV); Chronic hepatitis B (CHB);
Hepatitis B virus carriers; Telbivudine
|
